Morning Overview on MSN
A targeted pill and a custom mRNA vaccine are both beating back pancreatic cancer in early trials — cracking open one of medicine’s hardest tumors
Pancreatic ductal adenocarcinoma has a five-year survival rate of roughly 13 percent, according to the American Cancer ...
Morning Overview on MSN
Two new pancreatic cancer treatments — a targeted pill and a personalized mRNA vaccine — are beating back one of medicine’s deadliest tumors in early trials
Pancreatic cancer has long been oncology’s most stubborn adversary. Fewer than 13% of patients survive five years after ...
The mRNA vaccines and therapeutics market is poised for robust growth, driven by expanding applications beyond COVID-19, ...
Vaccines using mRNA technology weren’t immune to the latest round of federal research cuts. Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he’s pulling the plug on ...
WASHINGTON (AP) — So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel Prize-winning technology to try to develop vaccines and ...
I n December 2020, mRNA vaccines leapt into the limelight as a response to the COVID-19 pandemic. To date, millions of people ...
Engineers from the University of Houston, MIT and Harvard have developed a new mRNA-based strategy that dramatically amplifies the T-cell response to vaccines - an advance that could lead to far more ...
After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu ...
Tests with rodents suggest an mRNA vaccine in development offers protection against three strains of Ebola virus, including the one behind the current crisis ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results